Brokerages Set 2seventy bio, Inc. (NASDAQ:TSVT) Target Price at $7.20

2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) has been given a consensus rating of "Moderate Buy" by the six ratings firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, two have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $7.20.

Separately, Weiss Ratings reiterated a "sell (e+)" rating on shares of 2seventy bio in a research note on Saturday, February 1st.

2seventy bio Trading Down 0.4 %

Shares of NASDAQ:TSVT traded down $0.01 on Thursday, hitting $2.54. 153,720 shares of the company were exchanged, compared to its average volume of 253,013. The firm has a market capitalization of $131.03 million, a P/E ratio of -1.37 and a beta of 1.74. 2seventy bio has a 1-year low of $2.29 and a 1-year high of $6.40. The stock's 50 day moving average price is $2.80 and its 200 day moving average price is $3.88.

Institutional Investors Weigh In On 2seventy bio

A number of institutional investors have recently modified their holdings of the business. Bank of America Corp DE grew its position in shares of 2seventy bio by 317.1% in the fourth quarter. Bank of America Corp DE now owns 2,515,897 shares of the company's stock valued at $7,397,000 after purchasing an additional 1,912,771 shares during the period. Regeneron Pharmaceuticals Inc. purchased a new position in 2seventy bio in the 4th quarter valued at about $3,689,000. Western Standard LLC acquired a new stake in 2seventy bio in the 3rd quarter worth about $1,350,000. Monimus Capital Management LP purchased a new stake in 2seventy bio during the 4th quarter worth approximately $775,000. Finally, Dimensional Fund Advisors LP raised its stake in 2seventy bio by 68.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 475,118 shares of the company's stock valued at $1,397,000 after purchasing an additional 193,305 shares during the last quarter. 93.90% of the stock is currently owned by institutional investors and hedge funds.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.